INTRODUCTION {#sec1-1}
============

Physiologic changes during pregnancy are known to predispose to biliary disease.\[[@ref1][@ref2]\] High levels of estrogen stimulate hepatic production and secretion of cholesterol.\[[@ref3][@ref4]\] Rising progesterone also delays emptying of the gallbladder, which causes bile stasis and slows the release of bile acids that bind cholesterol.\[[@ref3][@ref4]\] Together, these lead to the development of cholesterol gallstones. This risk is higher with each pregnancy, and multiparous women are 10 times more likely to develop biliary complications \[[Figure 1](#F1){ref-type="fig"}\].\[[@ref5]\] In a prospective study of 3,200 pregnant women without cholelithiasis on baseline abdominal ultrasound (US), new cholelithiasis or bile sludge was observed in 7.1% at second trimester, 7.9% at third trimester, and up to 10.2% at 6 weeks postpartum.\[[@ref6]\] Of these, about 1.2% developed symptoms, and 10% of those with symptoms later developed serious complications such as acute cholecystitis, cholangitis, symptomatic choledocholithiasis, biliary strictures, or biliary pancreatitis that would necessitate therapeutic intervention.\[[@ref6][@ref7]\]

![Pathophysiology of gallstone formation in pregnancy](SJG-25-341-g001){#F1}

Although the physiology of pregnancy itself increases the risk of biliary pathology, the management of these conditions in this patient population is poorly studied thus far. The mainstay in biliary intervention is endoscopic retrograde cholangiopancreatography (ERCP), which is therapeutic for many of these diseases.\[[@ref8]\] In addition to the usual risks associated with ERCP, some inherent concerns arise in a pregnant female, including but not limited to exposure to radiation, medication teratogenicity, anesthesia, and changes in maternal anatomy.\[[@ref3]\] The specific relative risks of these effects are not well established because current case studies are limited by small sample size. As opposed to esophagogastroduodenoscopy (EGD) or colonoscopy, ERCP requires real-time prolonged X-ray with significant amount of fluoroscopic radiation, which is a potential cause of developmental complications in utero. One study with 15 patients showed that on average, fluoroscopy time was 3.2 min \[standard deviation (SD) ± 1.8 min\] with total 3.1 millisievert (mSV) (SD ± 1.64 mSV) of radiation; in general, it is recommended during first trimester to limit exposure to less than 1 mSV, and over the entire pregnancy less than 5 mSV.\[[@ref4]\]

Another concern is that the usual medications for sedation used during endoscopy are poorly studied in pregnant women. The most commonly used agents are propofol and ketamine.\[[@ref9][@ref10]\] Both drugs at moderate doses are category B drugs and considered relatively safe to use in pregnancy due to rapid onset and short duration of effect.\[[@ref9][@ref10]\] Of note, they require strict monitoring of levels by an experienced anesthesiologist and have not been well studied during first trimester pregnancy.\[[@ref9]\] Other commonly used endoscopy agents such as benzodiazepines, meperidine, and narcotics are usually avoided due to their lower threshold for causing fetal neurobehavioral depression and potential birth defects.\[[@ref4][@ref9]\] Finally, the usual post-ERCP adverse outcomes including postsphincterotomy bleeding (PSB), infection, pancreatitis, and perforation can have greater consequences in a pregnant woman.\[[@ref3]\] Even less documented are any potential causal links between ERCP and induction of early labor, premature rupture of membranes, or even spontaneous abortion.\[[@ref11]\]

Due to these concerns and the precarious nature of pregnancy itself, ERCP has historically been avoided in pregnancy. With the elevated risk of biliary disease that can occur in this patient population, avoidance of therapeutic measures can also become a cause of significant morbidity and mortality.\[[@ref3]\] Currently, the management of these complications is poorly defined, and each case is decided on an individual basis -- which can lead to clinician bias and postponement of critical care. Misunderstanding and misrepresentation of best standard of practice can lead to recurrent pain symptoms, high emergency department visits, more frequent hospitalization, or even death.\[[@ref12]\] Fear of intervention stems from lack of access to information about the exact benefits versus risks. Available studies are few and scattered, so here we present a meta-analysis of retrospective case studies on ERCP in pregnancy to compare outcomes, establish methods to minimize risk of the procedure, and have better understanding of the procedure outcomes that can be used by gastroenterologists and physicians in future patient care.

MATERIALS AND METHODS {#sec1-2}
=====================

Search strategy {#sec2-1}
---------------

We performed a literature search using the keywords "ERCP," "endoscopic retrograde cholangiopancreatography," "pregnancy," "endoscopy," and "fluoroscopy" in various combinations to identify original studies published in English from PubMed, Medline/Ovid, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science, and Google Scholar databases, through April 18^th^, 2018.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

We included studies that reported outcomes of pregnant patients who underwent ERCP. We excluded studies that reported other endoscopic procedures in pregnancy.

Study selection and data extraction {#sec2-3}
-----------------------------------

Two authors (M.A. and M.J.) independently screened titles and abstracts. They obtained full articles that met the inclusion and exclusion criteria, and after an independent review, they extracted the data. For all phases, discrepancies were resolved in consultation with two other authors (M.M. and A.H.). We also hand-searched the eligible articles. Forty-seven studies relevant to inclusion criteria were added. The actual numbers of ERCP cases were collected from tables and manuscript text in each study. When actual data were not presented in certain studies, two authors (J.Y. and M.A.) directly contacted the corresponding authors of their studies to obtain the data. Since data were from previously published studies, an institutional review board approval was waived. Finally, 27 studies were selected. [Figure 2](#F2){ref-type="fig"} presents the study selection process in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.\[[@ref13]\] A summary of studies is shown in [Table 1](#T1){ref-type="table"}.\[[@ref11][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref22][@ref23][@ref24][@ref25][@ref26][@ref27][@ref28][@ref29][@ref30][@ref31][@ref32][@ref33][@ref34][@ref35][@ref36][@ref37][@ref38][@ref39]\]

![Study selection process](SJG-25-341-g002){#F2}

###### 

Summary of studies

  Studies                                  Duration    Location    Type     No. of patients   Intervention            Mean age      Mean gestational age   No of ERCP in 1st, 2nd, 3rd trimester   Fetal complications                Maternal nonpregnancy-related complications        Maternal pregnancy-related complications   Duration of FU
  ---------------------------------------- ----------- ----------- -------- ----------------- ----------------------- ------------- ---------------------- --------------------------------------- ---------------------------------- -------------------------------------------------- ------------------------------------------ ------------------------
  Ludvigsson *et al*.\[[@ref14]\] 2017     1992-2011   Sweden      Cohort   58                ERCP unspecified        Unspecified   Unspecified            Unspecified                             3 major congenital malformations   0                                                  3 Preterm labor                            Unspecified
  Mali\[[@ref15]\] 2016                    1994-2014   USA         Cohort   6                 ERCP unspecified        25.7          24.4 weeks             0, 1, 5                                 0                                  1 PEP                                              0                                          Unspecified
  Inamdar *et al*.\[[@ref16]\] 2016        2008-2009   USA         Cohort   907               ERCP unspecified        26.06         Unspecified            Unspecified                             Unspecified                        109 PEP                                            16 Preterm labor                           Unspecified
  İlhan *et al*.\[[@ref17]\] 2016          2010-2015   Turkey      Cohort   4                 NR-ERCP                 Unspecified   Unspecified            Unspecified                             0                                  0                                                  0                                          Unspecified
  Ersoz *et al*.\[[@ref18]\] 2016          2002-2013   Turkey      Cohort   22                NR-ERCP                 26            26                     2,3,17                                  0                                  2 PEP                                              0                                          6 months
  Lee *et al*.\[[@ref19]\] 2015            2002-2013   Korea       Cohort   10                Rad-ERCP and NR-ERCP    30.7          16.8 weeks             4, 8, 1                                 0                                  1 Hyperamylasemia                                  0                                          Unspecified
  Fine *et al*.\[[@ref20]\] 2014           2002-2012   USA         Cohort   20                Rad-ERCP                26.4          second trimester       Unspecified                             0                                  2 PEP                                              0                                          Unspecified
  Yang *et al*.\[[@ref21]\] 2013           2003-2008   China       Cohort   24                NR-ERCP                 28.5          Unspecified            Unspecified                             0                                  2 PSB                                              4 Preterm labor                            Unspecified
  Vohra *et al*.\[[@ref22]\] 2013          2008-2012   USA         Cohort   6                 NR-ERCP (ERCP w EUS)    29            25 weeks               Unspecified                             0                                  0                                                  0                                          Unspecified
  Smith *et al*.\[[@ref23]\] 2013          2001-2009   USA         Cohort   35                Rad-ERCP                25            18.9 weeks             14, 11, 10                              0                                  2 PEP, 2 PSB, 1 ARDS (fatal) and 1 cholecystitis   0                                          Unspecified
  Agcaoglu *et al*.\[[@ref24]\] 2013       2007-2012   Turkey      Cohort   5                 NR-ERCP                 26            20 Weeks               Unspecified                             0                                  0                                                  0                                          30 days
  García-Cano *et al*.\[[@ref25]\] 2012    2002-2012   Spain       Cohort   11                Rad-ERCP and NR-ERCP    30.6          Unspecified            1, 4, 6                                 0                                  1 Hyperamylasemia                                  0                                          Unspecified
  Krishnan *et al*.\[[@ref26]\] 2011       2006-2010   India       Cohort   6                 Rad-ERCP and NR-ERCP    28.3          24 weeks               1, 2, 3                                 0                                  0                                                  0                                          30 days
  Tang *et al*.\[[@ref27]\] 2009           2000-2006   China       Cohort   65                Rad-ERCP                25.8          Unspecified            17, 20, 31                              4 LBW                              11 PEP                                             5 Preterm labor                            Unspecified
  Bani Hani *et al*.\[[@ref28]\] 2009      2002-2007   Jordan      Cohort   10                Rad-ERCP                24.3          18.4 weeks             2, 5, 3                                 0                                  1 PEP                                              0                                          1 week
  Daas *et al*.\[[@ref29]\] 2009           2005-2009   USA         Cohort   10                Rad-ERCP and NR-ERCP    23.5          20 weeks               Unspecified                             0                                  0                                                  0                                          30 days
  Akcakaya *et al*.\[[@ref30]\] 2009       2000-2008   Turkey      Cohort   6                 NR-ERCP                 28            23 weeks               Unspecified                             0                                  0                                                  0                                          Unspecified
  Sharma and Maharshi\[[@ref31]\] 2008     1996-2005   India       Cohort   11                NR-ERCP (2-step ERCP)   Unspecified   Unspecified            2, 6, 3                                 0                                  0                                                  0                                          4 weeks after delivery
  Shelton *et al*.\[[@ref32]\] 2008        2000-2007   USA         Cohort   21                NR-ERCP                 27            19 weeks               Unspecified                             1 LBW                              1 PEP                                              1 Preterm labor                            Unspecified
  Gawrychowski *et al*.\[[@ref33]\] 2007   2007        Poland      Cohort   4                 NR-ERCP                 36            33 weeks               0, 0, 4                                 0                                  0                                                  0                                          Unspecified
  Quan *et al*.\[[@ref34]\] 2006           1997-2004   Singapore   Cohort   3                 Rad-ERCP                27.8          21.5 weeks             0, 2, 2                                 0                                  0                                                  0                                          Unspecified
  Gupta *et al*.\[[@ref35]\] 2005          1994-2004   India       Cohort   18                NR-ERCP (ERCP w EUS)    Unspecified   Unspecified            4, 6, 8                                 0                                  1 PEP and 1 PSB                                    1 Preterm labor                            6 years
  Kahaleh *et al*.\[[@ref11]\] 2004        1995-2003   USA         Cohort   17                Rad-ERCP                Unspecified   18.6 weeks             Unspecified                             0                                  1 PEP and 1 PSB                                    2 Preeclampsia                             Unspecified
  Simmons *et al*.\[[@ref36]\] 2004        2001-2002   USA         Cohort   6                 NR-ERCP                 27            16 weeks               Unspecified                             1 IUGR                             0                                                  2 Preterm labor                            Unspecified
  Tham *et al*.\[[@ref37]\] 2003           1998-2003   USA         Cohort   15                Rad-ERCP                28.9          25 weeks               1, 5, 9                                 0                                  1 PEP                                              0                                          Unspecified
  Sungler *et al*.\[[@ref38]\] 2000        1994-1998   Austria     Cohort   5                 Rad-ERCP                Unspecified   Unspecified            0, 4, 1                                 0                                  0                                                  0                                          Unspecified
  Barthel *et al*.\[[@ref39]\] 1998        1991-1998   USA         Cohort   3                 Rad-ERCP                20            24 weeks               Unspecified                             0                                  1 PEP                                              0                                          6 months-2 years

ERCP: Endoscopic retrograde cholangiopancreatography; FU: Follow-up; Rad-ERCP: Radiation ERCP; NR-ERCP: Nonradiation ERCP; EUS: Endoscopic ultrasound; PEP: Post-ERCP pancreatitis; PSB: Postsphincterotomy bleeding; ARDS: Acute respiratory distress syndrome; LBW: Low birth weight; IUGR: Intrauterine growth restriction

Study outcomes {#sec2-4}
--------------

We divided outcomes of ERCP in pregnancy into three categories. First, fetal outcomes, which included any fetal adverse outcomes reported during pregnancy, labor, or the follow-up period like intrauterine growth retardation, congenital malformations, fetal demise, and low birth weight. Second, maternal pregnancy-related outcomes, which included any pregnancy adverse outcomes reported after the ERCP procedure such as preterm labor, preeclampsia, or bleeding. Third, maternal nonpregnancy-related outcomes, which included all ERCP-related adverse outcomes that are not related to pregnancy, such as post-ERCP pancreatitis (PEP), PSB, or cholecystitis.

Quality assessment {#sec2-5}
------------------

We used the Newcastle--Ottawa Scale (NOS) to assess the risk of bias in the included studies.\[[@ref40][@ref41]\] Risk of bias in relation to selection, comparability, and assessment of the exposure/outcome was assessed according to nine items using a star allocation scheme. Stars were allocated if a study was deemed to have a low risk of bias within each item, according to the coding manual provided.\[[@ref42]\] A study was categorized as being of low risk of bias if a total of 8--9 stars were allocated, medium risk of bias if 6--7 stars were allocated, and of high risk of bias if the study was given ≤5 stars.

Data synthesis and analysis {#sec2-6}
---------------------------

We combined individual study results to calculate the pooled odds ratio (OR) and 95% confidence intervals (CIs) using the random effects method.\[[@ref43]\] Between-study heterogeneity was assessed using the I^2^ static values of 50%, representing extensive statistical inconsistency. Subgroup analysis was performed to examine effects of irradiation on fetal and maternal outcomes. All analyses were performed using Comprehensive Meta-Analysis version 3 (Biostat Inc., Englewood, NJ, USA; 2014). A two-sided *P* value \<0.05 was considered statistically significant.

RESULTS {#sec1-3}
=======

A total of 1,307 patients from 27 retrospective studies were analyzed. Baseline characteristics from pooled study participants are reported in [Table 1](#T1){ref-type="table"}. The characteristics were grouped by adverse outcomes (fetal, maternal pregnancy-related, and maternal nonpregnancy-related): fetal adverse outcomes (*n* = 9), maternal pregnancy-related outcomes (*n* = 22), maternal nonpregnancy-related outcomes (*n* = 143).

[Figure 3](#F3){ref-type="fig"} presents the meta-analysis results of the overall adverse events in pregnant patients; the pooled event rate was 15.9% (95% CI = 0.132--0.19). The results were statistically significant (*P* \< 0.01). Heterogeneity was low (Q = 26, *P* = 0.370, I^2^= 6.3%). Inamdar *et al*.\'s study could be an outlier resulting in increasing the degree of heterogeneity.\[[@ref16]\] When this study was removed from current meta-analysis, the magnitude of pooled event rate slightly increased to 18.1% (95% CI 0.144--0.226) and heterogeneity dropped to near zero (I^2^\< 0.01%).

![Meta-analysis result of overall adverse events in pregnant patients undergoing ERCP](SJG-25-341-g003){#F3}

The large number of patients in Inamdar *et al*. generated the outlier effect \[[Figure 4](#F4){ref-type="fig"}\].\[[@ref16]\]

![Overall adverse events in pregnant patients undergoing ERCP without outlier effect](SJG-25-341-g004){#F4}

[Figure 5](#F5){ref-type="fig"} presents the meta-analysis results of the fetal adverse outcomes; the pooled event rate was 5.4% (95% CI = 0.035--0.083). The pooled event rate for maternal pregnancy-related adverse events in pregnant patients was 6.1% (95% CI = 0.040--0.093). The pooled event rate for maternal nonpregnancy-related adverse events in pregnant patients was 11.9% (95% CI = 0.102--0.138). The quality of evidence started low because analyzed studies were all observational. Symmetrical funnel plot was consistent with the absence of publication bias. No evidence of publication bias by Egger\'s regression test for all-cause was found. The final quality of evidence was high because no serious limitation was found in the NOS as shown in [Table 2](#T2){ref-type="table"}.

![Fetal outcomes\' meta-analysis](SJG-25-341-g005){#F5}

###### 

Newcastle-Ottawa Scale for the included studies

  Reference                                Selection                   Comparability                                             Outcome                                                                                                                                                     Overall quality assessment score (of a maximum of 9)                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  ---------------------------------------- --------------------------- --------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------ --------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------- ---
  Agcaoglu *et al*.\[[@ref24]\] 2013       Not representative          Nonexposed cohort: N/A                                    \*NR- ERCP                                                                                                                                                  \*No comments regarding patient's pre-ERCP history                                    Controls N/A                                                       \*Independent blind assessment                                        Long-term FU N/A (maternal; postprocedure, fetal: at delivery, 30 days post-delivery)                        \*No maternal/fetal adverse events and complications                                                                                                             4
  Akcakaya *et al*.\[[@ref30]\] 2009       Not representative          Nonexposed cohort: N/A                                    \*NR-ERCP                                                                                                                                                   One patient with biliary fistula                                                      Controls N/A                                                       \*Independent blind assessment                                        Long-term FU N/A (until discharge)                                                                           \*1 maternal complication (fistula persistent, which was present before the 1^st^ ERCP)No fetal complication                                                     3
  Barthel *et al*.\[[@ref39]\] 1998        Not representative          Nonexposed cohort: N/A                                    \*Endoscopic sphincterotomy                                                                                                                                 \*No comments regarding patient's pre-ERCP history                                    Controls N/A                                                       \*Independent blind assessment, phone FU for 1 patient                FU 6 months to 2 years                                                                                       1 PEP, 1 preterm birth                                                                                                                                           3
  Daas *et al*.\[[@ref29]\] 2009           \*Somewhat representative   Nonexposed cohort: N/A                                    \*ERCP (limited use of fluoroscopy in 6 cases)                                                                                                              \*No comments regarding patient's pre-ERCP history                                    Controls N/A                                                       \*Independent blind assessment                                        Maternal: post-ERCP FUFetal: at delivery and 30 days post-delivery                                           \*No maternal/fetal adverse events and complications                                                                                                             5
  Ersoz *et al*.\[[@ref18]\] 2016          \*Somewhat representative   Nonexposed cohort: N/A                                    \*NR-ERCP                                                                                                                                                   \*No comments regarding patient's pre-ERCP history except 1 patient with GDM          Controls N/A                                                       \*Independent blind assessment                                        \*Maternal: FU for 6 months for post-ERCP late complicationsFetal: at delivery and 6 months post-delivery    Maternal: mild post-ERCP complication (bleeding, pain, mild pancreatitis)No fetal complication                                                                   5
  Fine *et al*.\[[@ref20]\] 2014           \*Somewhat representative   Nonexposed cohort: N/A                                    \* ERCP with or without fluoroscopy                                                                                                                         \*No comments regarding patient's pre-ERCP history                                    \*Controls for age and sex                                         \*Independent blind assessment                                        Long-term FU N/A                                                                                             \* 2 PEP but both had multiple stones on ERCP                                                                                                                    6
  García-Cano *et al*.\[[@ref25]\] 2012    \*Somewhat representative   Nonexposed cohort: N/A                                    \* ERCP with or without fluoroscopy                                                                                                                         \*No comments regarding patient's pre-ERCP history except showing symptoms for CBDS   Controls N/A                                                       \*Independent blind assessment                                        Long-term FU N/A                                                                                             1 hyperamylasemia                                                                                                                                                4
  Gawrychowski *et al*.\[[@ref33]\] 2007   Not representative          Nonexposed cohort: N/A                                    \*ERCP with papillotomy                                                                                                                                     \*1 patient with previous cholecystectomy                                             Controls N/A                                                       \*Independent blind assessment                                        Maternal: postprocedureFetal: at delivery                                                                    \*Minimal risk of PEPNo increase in fetal loss                                                                                                                   4
  Gupta *et al*.\[[@ref35]\] 2005          \*Somewhat representative   Nonexposed cohort: N/A                                    \*ERCP with or without fluoroscopy                                                                                                                          \*No comments regarding patient's pre-ERCP history                                    Controls N/A                                                       \*Independent blind assessment                                        \*11 of 18 patients were FU for babies (age 1-11)                                                            Maternal: mild post-ERCP complication, 1 preterm deliveryNo fetal complication                                                                                   5
  Bani Hani *et al*.\[[@ref28]\] 2009      \*Somewhat representative   Nonexposed cohort: N/A                                    \*ERCP                                                                                                                                                      \*3 patients with previous cholecystectomy                                            Controls N/A                                                       \*Independent blind assessment                                        Maternal: postprocedureFetal: till neonatal period (screening for congenital anomalies/malformations done)   \*No maternal/fetal adverse events and complications noted.                                                                                                      5
  İlhan *et al*.\[[@ref17]\] 2016          \*Probable representative   Nonexposed cohort: conservative treatment                 \*ERCP in 4, Cholecystectomy in 15 patients                                                                                                                 \*No comments regarding patient's pre-ERCP history                                    Controls available, but study does not control for other factors   \*Independent blind assessment                                        Long-term FU N/A                                                                                             1 Maternal death/Perinatal complications (preterm delivery, missed abortion, LBW), no fetal abnormalities                                                        4
  Inamdar *etal*.\[[@ref16]\] 2016         \*Truly representative      Nonexposed cohort: N/A                                    \*ERCP                                                                                                                                                      \*No comments regarding patient's pre-ERCP history                                    \*Controls were available; age-matched                             \*Independent blind assessment                                        Long-term FU N/A                                                                                             \*No deaths in pregnant group, no difference in maternal mortality, similar fetal distress/fetal loss rate compared to national average                          6
  Kahaleh *et al*.\[[@ref11]\] 2004        \*Somewhat representative   Nonexposed cohort: N/A                                    \*ERCP with Fluoroscopy performed/Radiation exposure measured by TLD in 15 patients                                                                         \*No comments regarding patient's pre-ERCP history                                    Controls N/A                                                       \*Independent blind assessment                                        Long-term FU N/A                                                                                             1 PSB, 2 obstetric complications (preeclampsia-\>induced labor)                                                                                                  4
  Krishnan *et al*.\[[@ref2]\] 2011        Not representative          Nonexposed cohort: N/A                                    \*ERCP with or without fluoroscopy                                                                                                                          \*No comments regarding patient's pre-ERCP history                                    Controls N/A                                                       \*Independent blind assessment                                        Maternal: postprocedureFetal: at delivery and 30 days after delivery                                         \*No maternal/fetal adverse events and complications noted                                                                                                       4
  Lee *et al*.\[[@ref19]\] 2015            \*Somewhat representative   Nonexposed cohort: N/A                                    \*ERCP(with or without fluoroscopy) or EUS                                                                                                                  \*No comments regarding patient's pre-ERCP history                                    Controls N/A                                                       \*Independent blind assessment/self-report for long-term FU (phone)   \*Maternal: postprocedureFetal: at delivery and long-term FU by phone                                        1 hyperamylasemia,1 acute pulmonary edema (-\>artificial abortion)3 preterm births, 1 LBW                                                                        5
  Ludvigsson *et al*.\[[@ref14]\] 2017     \*Truly representative      \*Mother without any endoscopy                            \*Any endoscopy (EGD, colonoscopy, sigmoidoscopy, ERCP)                                                                                                     outcomes likely due to disease activity                                               \*\*Study controls matched for more than 3 factors                 \*Independent blind assessment                                        Long-term FU N/A                                                                                             For any endoscopy: higher preterm birth percentage (but lower in ERCP group), higher SGA percentage, no difference in congenital malformations and stillbirths   6
  Mali\[[@ref15]\] 2016                    Not representative          \*Pregnant women with pancreatitis treated without ERCP   \*ERCP                                                                                                                                                      \*No comments regarding patient's pre-ERCP history                                    Controls available, but study does not control for other factors   \*Independent blind assessment                                        Long-term FU N/A                                                                                             \*No maternal/fetal adverse events and complications                                                                                                             5
  Quan *et al*.\[[@ref34]\] 2006           Not representative          Nonexposed cohort: N/A                                    \*ERCP or oral gastroduodenoscopy                                                                                                                           \*No comments regarding patient's pre-ERCP history                                    Controls N/A                                                       \*Independent blind assessment/telecommunication FU                   \*long term FU by telecommunication                                                                          \*No maternal/fetal adverse events and complications                                                                                                             5
  Sharma and Maharshi\[[@ref31]\] 2008     \*Somewhat representative   Nonexposed cohort: N/A                                    \*2 stage endoscopic approach:1) biliary sphincterotomy and stenting (without any fluoroscopy or US)2) definitive ERCP and stone clearance after delivery   \*No comments regarding patient's pre-ERCP history                                    Controls N/A                                                       \*Independent blind assessment                                        \*8 of 11 patients: regular FU for 2-6 years after procedure                                                 \*No maternal/fetal adverse events and complications                                                                                                             6
  Shelton *etal*.\[[@ref32]\] 2008         \*Somewhat representative   Nonexposed cohort: N/A                                    \*NR-ERCP                                                                                                                                                   \*No comments regarding patient's pre-ERCP history                                    Controls N/A                                                       \*Independent blind assessment                                        Long-term FU N/A                                                                                             1 mild PEP, 1 IUGR                                                                                                                                               4
  Simmons *et al*.\[[@ref36]\] 2004        Not representative          Nonexposed cohort: N/A                                    \*NR-ERCP                                                                                                                                                   \*No comments regarding patient's pre-ERCP history                                    Controls N/A                                                       \*Independent blind assessment                                        Long-term FU N/A                                                                                             No maternal complications,2 infants born prematurely (1 of them with IUGR, ARDS),2 mothers: lost to FU                                                           3
  Smith *et al*.\[[@ref23]\] 2013          \*Probable representative   Nonexposed cohort: N/A                                    \*ERCP with fluoroscopy                                                                                                                                     5 patients had cholecystectomy prior to ERCP                                          Controls N/A                                                       \*Independent blind assessment                                        Long-term FU N/A                                                                                             2 PEP, 2 PSB,1 ARDS (fatal) and 1 cholecystitisNo details on the fetal complications                                                                             3
  Sungler *etal*.\[[@ref38]\] 2000         Not representative          \*32 patients not exposed to ERCP                         ERCP and/or laparoscopic surgery                                                                                                                            \*No comments regarding patient's pre-ERCP history                                    Controls available, but study does not control for other factors   \*Independent blind assessment                                        \*FU with mother and infant to date                                                                          \*No maternal/fetal adverse events and complications                                                                                                             5
  Tang *et al*.\[[@ref27]\] 2009           \*Probable representative   Nonexposed cohort: N/A                                    \*ERCP with fluoroscopy                                                                                                                                     \*No comments regarding patient's pre-ERCP history                                    Controls N/A                                                       \*Independent blind assessment                                        Long-term FU N/A                                                                                             11 PEP, 5 preterm labor, and 4 LBW                                                                                                                               4
  Tham *et al*.\[[@ref37]\] 2003           \*Somewhat representative   Nonexposed cohort: N/A                                    \*ERCP with fluoroscopy                                                                                                                                     \*No comments regarding patient's pre-ERCP history                                    Controls N/A                                                       \*Independent blind assessment                                        Long-term FU N/A                                                                                             1 PEP, and 3 needed laparoscopic cholecystectomy                                                                                                                 4
  Vohra *et al*.\[[@ref22]\] 2013          \*somewhat representative   \*4 patients EUS                                          \*NR-ERCP                                                                                                                                                   \*No comments regarding patient's pre-ERCP history                                    Controls available, but study does not control for other factors   \*Independent blind assessment                                        Long-term follow-up N/A                                                                                      \*No maternal/fetal adverse events and complications                                                                                                             6
  Yang *et al*.\[[@ref21]\] 2013           \*Somewhat representative   Nonexposed cohort: N/A                                    \*NR-ERCP                                                                                                                                                   \*No comments regarding patient's pre-ERCP history                                    Controls N/A                                                       \*Independent blind assessment                                        Long-term follow-up N/A                                                                                      2 PSB, 4 preterm labor                                                                                                                                           4

ERCP: Endoscopic retrograde cholangiopancreatography; FU: Follow-up; NR-ERCP: Nonradiation ERCP; EUS: Endoscopic ultrasound; PEP: Post-ERCP pancreatitis; PSB: Postsphincterotomy bleeding; ARDS: Acute respiratory distress syndrome; LBW: Low birth weight; IUGR: Intrauterine growth restriction; SGA: Small for gestational age; N/A: Not available

Subgroup analysis results were done by radiation exposure. Nine of 27 studies included both ERCP with radiation and NR-ERCP. They did not specify the outcomes based on radiation exposure. Nine studies included only NR-ERCP and another nine studies included radiation ERCP. NR-ERCPs were performed using three different techniques: abdominal US-guided ERCP, endoscopic ultrasound (EUS)-guided ERCP, and choledochoscopy-guided ERCP. Overall adverse events were less prevalent in the NR-ERCP group (pooled event rate of 17.6%, 95% CI = 0.109--0.272) versus radiation ERCP group (pooled event rate 21.6%, 95% CI = 0.154--0.294). There was no significant difference in the fetal adverse outcomes between the radiation ERCP group (pooled event rate 5.2%, 95% CI = 0.026--0.101) and the NR-ERCP group (pooled event rate 6.2%, 95% CI = 0.027--0.137).

Maternal pregnancy-related adverse outcomes were less prevalent in the radiation ERCP group (pooled event rate 7.1%, 95% CI = 0.039--0.125) in comparison to the NR-ERCP group (pooled event rate 12.0%, 95% CI = 0.065--0.211). However, the overlap in CI makes the results less statistically significant. Maternal nonpregnancy-related outcomes were more prevalent in the radiation ERCP group (pooled event rate 14.9%, 95% CI = 0.102--0.211) in comparison to 7.6% (95% CI = 0.038--0.145) in the NR-ERCP group. Again, the CI overlap affects the statistical significance despite the low *P* value. All results were statistically significant with *P* value \<0.01.

DISCUSSION {#sec1-4}
==========

To our knowledge, this is the first meta-analysis of the ERCP outcomes in pregnancy and the first to provide a head-to-head comparison between radiation ERCP and NR-ERCP. In this systematic review and meta-analysis, we found ERCP to be a relatively safe procedure during pregnancy. Intraoperatively, no complications were reported. Maternal post-ERCP adverse events included pancreatitis, PSB, cholecystitis, and one incidence of acute respiratory distress syndrome resulting in the only case of maternal death. The rate of ERCP-related maternal adverse outcomes was found to be slightly higher than the usual ERCP outcomes.\[[@ref16]\] ERCP was also associated with an increased risk of preterm labor and preeclampsia, but there were no reported cases of abortion, bleeding, or intrauterine fetal death. With regard to fetal outcomes, ERCP was found to be relatively safe on the fetus without any reported cases of fetal congenital malformation or stillbirth, despite the increased risk of preterm labor and low birth weight. A subgroup analysis was performed to compare the outcomes of radiation ERCP versus NR-ERCP. NR-ERCP had a higher safety profile in terms of maternal nonpregnancy-related outcomes with lower rates of PEP and PSB. Regarding fetal outcomes, NR-ERCP showed no superiority to radiation ERCP. No congenital malformations were reported in both groups. However, both groups had an increased risk of preterm labor and intrauterine growth retardation.

Radiation exposure during fluoroscopy time in ERCP is used to visualize the anatomy of the biliary tract and ensure safe and successful biliary cannulation, stone extraction, and sphincterotomy. Different NR-ERCP techniques have recently been introduced to avoid possible radiation exposure fetal malformations. However, these techniques were not associated with better fetal outcomes in comparison to the radiation ERCP. This may be attributable to the fact that radiation exposure in ERCP is lower than the exposure needed to cause congenital fetal anomalies.\[[@ref44]\] Fetal risk of anomalies, growth restriction, or abortion has not been reported with radiation exposure of less than 50 mGy, a level above the range of exposure in ERCP according to the American College of Obstetrics and Gynecology.\[[@ref44]\] In one study, the estimated fetal radiation exposure in 17 cases of ERCP with limited fluoroscopy time (range 1--48 s) is 0.4 mGy (range 0.01--1.8 mGy).\[[@ref11]\] Other factors that can affect the fetal absorbed dose of irradiation include orientation of the fetus, fetus size, procedure position, and body composition of the mother.\[[@ref45]\] Although most of the fetal irradiation exposure comes from the radiation diffused from the maternal tissue, application of a lead apron is still routinely recommended.\[[@ref11]\] Several other strategies are recommended to reduce the fetal irradiation exposure and complications, including decreasing fluoroscopy time, minimizing exposure areas, and application of electric grounding pad higher in the posterior thoracic wall level to avoid transmission of electric current to the fetus.\[[@ref46][@ref47]\] Gestational age at the time of irradiation exposure is also crucial. Significant irradiation exposure before 16 weeks of gestational age has a higher risk of intellectual disability.\[[@ref48]\]

The NR-ERCP group had lower rates of PEP and PSB in comparison to the radiation ERCP. This finding is unexpected and should be interpreted cautiously due to CI overlap. It may be attributable to the fact that NR-ERCP is a more sophisticated procedure which requires more equipment and a higher level of expertise in endoscopy and is thus only performed by high-volume practitioners. NR-ERCP is achieved through empirical bile aspiration technique and can be done with imaging guidance. Bile aspiration technique allows confirmation of common bile duct (CBD) cannulation and endoscopic sphincterotomy to be carried out without radiation, while imaging guidance can be provided by EUS, transabdominal US, or choledochoscopy. US allows recognition of the CBD stone site, confirmation of wire placement, and cannulation of the CBD. An US contrast agent (sulfur hexafluoride microbubbles) was injected through ERCP to improve visualization of the CBD as an alternative to fluoroscopy in a single case report.\[[@ref49]\] No fetal complications were reported in this case report; however, the safety profile of this contrast material on the fetus is still unclear. US-guided ERCP showed higher rate of stone clearance in comparison to empirical NR-ERCP (89% vs 60%, *P* \< 0.05) and lower complication rates (14% vs 3%, *P* \< 0.05).\[[@ref50]\] EUS can be carried out in the same session before ERCP to determine the number and site of stones before NR-ERCP is carried out with bile aspiration technique to clear the CBD.\[[@ref51][@ref52]\] Another way to confirm biliary cannulation and stone clearance without radiation is by insertion of a choledochoscope through the working channel of EGD to directly visualize the bile duct.\[[@ref53]\] Due to the scarcity of available literature, there are currently no available data that compare EUS-guided ERCP or peroral choledochoscopy-guided ERCP to empiric NR-ERCP.

Two-stage ERCP technique was introduced in a few reports. During pregnancy, NR-ERCP with empiric biliary aspiration and CBD stenting is performed. After delivery, a repeat ERCP is performed to remove the stent and ensure CBD clearance.\[[@ref31]\] Extensive experience in ERCP is required in this technique as stent placement without fluoroscopy might lead to the stent misplacement either in the gallbladder or before the stone. A postprocedural US is required to confirm the position of the stent.

The following few points strengthen our confidence in the current meta-analysis results. First, statistical heterogeneity was very low. Second, the quality of the included studies was moderately high. Third, we found no evidence of publication bias. Nonetheless, we acknowledge several limitations. First, the risk of selection bias could have resulted in underreporting of ERCP adverse outcomes in pregnancy. Second, the duration of follow-up differed from one study to the other, and most patients were lost to follow-up 1 month after delivery. Third, studies were performed at different locations around the world with varying levels of expertise in endoscopy. Fourth, the heterogeneity in the NR-ERCP techniques could have affected the outcomes.

In conclusion, our findings support the notion that ERCP should continue to be the procedure of choice for bile duct decompression in pregnancy to prevent potentially life-threatening complications to both mother and fetus. Nonradiation techniques may decrease the risk of nonpregnancy-related outcomes, but do not impact fetal or pregnancy-related outcomes.
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